F.Nucleum induces PD-L1 expression by activating STING signaling and increases the accretion of interferon-γ (IFN-γ)+CD8+TIL during PD-L1 blockade therapy, thereby enhancing the anti-tumor response to PD-1/PD-L1 checkpoint blockade (57). Here, CD8A is linked to neoplasm.